Prostate cancer on the rise in 2022 April 29, 2022 Prostate cancer is a very common diagnosis. Did you know prostate cancer is estimated to be the second most common cancer diagnosis in American men?According t... Continue Reading
Genetic insights for more actionable and personalized prostate cancer March 25, 2022 Connect with us The AUA National meeting is centered around the exploration of the latest and groundbreaking advancements in urology, and th... Continue Reading
Prolaris® is advancing prostate cancer care at ASCO GU February 11, 2022 Prolaris now has 2 validated thresholds to make treatment decisions easier Prolaris is a prognostic, tumor-based biomarker test that measures the aggressive... Continue Reading
Prolaris® is Helping Urologists Reimagine Prostate Cancer Care November 2, 2021 This year’s LUGPA theme centers on re-imagining the practice of Urology. What better time than now to discover how incorporating genetic testing into your pr... Continue Reading
New Study Proves that Prolaris can Determine which Patients Can Safely Avoid ADT October 15, 2021 Historically, Urologists in practice have given Radiation Therapy (RT) or Androgen Deprivation Therapy (ADT) after initial prostate cancer treatment to red... Continue Reading
2021 Prostate Cancer Statistics April 15, 2021 According to the American Cancer Society, the number of newly diagnosed prostate cancer patients has increased by nearly 30% since 2020 and estimates there wil... Continue Reading
New Data Validating the Prolaris® Test to Guide Treatment for Prostate Cancer February 17, 2021 Myriad Genetics announces new data validating the prognostic power of the Prolaris multi-modal threshold and its ability to help predict which men with agg... Continue Reading
The Importance of Genetic Testing for Prostate Cancer P2 September 28, 2020 In the second webinar installment partnered with Prostate Health Education Network (PHEN), Dr. Keith Crawford MD, PHD will discuss new treatment and clinical t... Continue Reading
The Importance of Genetic Testing for Prostate Cancer P1 September 17, 2020 Myriad has partnered with the Prostate Health Education Network (PHEN) advocacy group to help educate patients and caregivers on the importance of genetic test... Continue Reading
1 in 6 Men with Prostate Cancer May Have a Hereditary, Disease-Causing Mutation September 17, 2020 Knowing the status of your patient’s BRCA 1/2 germline status is critical. Myriad hereditary cancer tests give you definitive and actionable risk stratificat... Continue Reading
The Prolaris Test Gave Me Information I Needed September 9, 2020 Byron Sparkman, 65, began getting his PSA levels checked about 10 years ago due to his family cancer history. His mother had breast cancer and his father had p... Continue Reading
New Treatment Options Available September 9, 2020 Every man with prostate cancer deserves to know his germline BRCA 1/2 status and recent changes now make that possible and easier than ever. Medicare has expan... Continue Reading
Genetic Testing Changed My Life September 4, 2020 After a visit with his family doctor, John Earp had a PSA of 13.96. With this new possible diagnosis of prostate cancer, he began to worry thinking about his e... Continue Reading
Medicare Expands Coverage for BRACAnalysis CDx in Prostate Cancer September 1, 2020 Myriad Genetics, a leader in molecular diagnostics and precision medicine, announced that Medicare has expanded coverage for BRACAnalysis CDx® for men with pr... Continue Reading
Not All Prostate Cancer is the Same March 26, 2020 Up to 1 in 6 prostate cancers are hereditary. If you have hereditary prostate cancer, your children and siblings have a 50% chance of having the same genetic m... Continue Reading